Back to News
Market Impact: 0.2
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
Source: globenewswire.com
Healthcare & Biotech
Agomab said the first patient has been dosed in NOV-ERA, its Phase 2b study evaluating ontunisertib in patients with symptomatic FSCD. The announcement marks the study's dosing milestone; no efficacy results or additional trial details were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
AGMB0.55
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
- Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales
- Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Palantir (PLTR) Q4 2025 Earnings: 70% Revenue Growth, Then an 11% Single-Day Crash
- AlphaSense Pricing: What Public Contract Data Shows in 2026